Paris, France

Time filter

Source Type

Patent
HRA Pharma | Date: 2016-11-15

The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.


Patent
HRA Pharma | Date: 2015-07-02

The invention relates to a method for providing regular contraception to a woman. Said method comprises administering a daily contraceptive amount of ulipristal acetate or a metabolite thereof over a period of at least 21 consecutive days.


Patent
HRA Pharma | Date: 2017-02-16

The subject of the present invention is a co-micronization product comprising an active ingredient selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and a pharmaceutically acceptable solid surfactant. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.


Patent
HRA Pharma | Date: 2017-05-10

The invention relates to a method for providing regular contraception to a woman. Said method comprises administering a daily contraceptive amount of ulipristal acetate or a metabolite thereof over a period of at least 21 consecutive days.


Patent
HRA Pharma | Date: 2016-06-17

The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.


Patent
HRA Pharma | Date: 2016-12-14

The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt%, at least one binding agent in an amount of 0 to 10 wt%, at least one disintegrating agent in an amount of 0.5 to 10 wt%, and at least one lubricant in an amount of 0 to 10 wt%.


Patent
HRA Pharma, French Institute of Health and Medical Research | Date: 2016-07-29

The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.


Patent
HRA Pharma and The United States Of America | Date: 2016-12-21

The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-llb-[4-N, N-dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.


The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.


Patent
HRA Pharma | Date: 2016-02-05

The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.

Loading HRA Pharma collaborators
Loading HRA Pharma collaborators